Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) will participate in the 41st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023. Executive Chairman William Doyle will speak at 7:30 a.m. PST on January 10, 2023, addressing analysts' questions. Additionally, Doyle and CFO Ashley Cordova will hold one-on-one meetings with investors. A live audio webcast of the presentation will be available on Novocure's Investor Relations page, along with a replay for at least 14 days post-event. Novocure focuses on extending survival in aggressive cancers through its innovative Tumor Treating Fields therapy.
- None.
- None.
ROOT,
A live audio webcast of the presentation and all presentation materials can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event. Novocure has used, and intends to continue to use, its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Headquartered in Root,
Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on
View source version on businesswire.com: https://www.businesswire.com/news/home/20221227005008/en/
Investors:
investorinfo@novocure.com
610-723-7427
Media:
media@novocure.com
610-723-7428
Source: Novocure
FAQ
When will Novocure participate in the J. P. Morgan Healthcare Conference?
Who is speaking for Novocure at the conference?
What time will Novocure's presentation begin at the conference?
How can I access Novocure's presentation materials?